GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
C8478 CB1R antagonist 1 -
C8497 KRAS inhibitor-9 -
C8512 PRLX-93936 dihydrochloride -
C8538 LPA2 antagonist 2 -
C8540 5-HT7 receptor ligand 1 -
C8552 LASSBio-873 -
A9969 BMS-470539 dihydrochlorideSummary: A highly selective melanocortin 1 receptor (MC-1R) agonist -
A9970 cis-Epoxysuccinic acidSummary: An agonist for the succinate receptor (SUCNR1/GPR91) -
A9986 Terlipressin diacetateSummary: A highly selective vasopressin V1 receptor agonist -
A9987 Levobunolol hydrochlorideSummary: A potent, non-selective β-adrenergic receptor antagonist

